Recombinant Human Neural Cell Adhesion Molecule 1 (NCAM1) Protein (His)

Name: Recombinant Human Neural Cell Adhesion Molecule 1 (NCAM1) Protein (His)
Brand: Beta LifeScience
SKU: BLC-03459P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Cluster of differentiation (cd) proteins, Featured cd protein molecules, Recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Neural Cell Adhesion Molecule 1 (NCAM1) Protein (His) is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P13591
Target Symbol	NCAM1
Synonyms	antigen MSK39 identified by monoclonal 5.1H11; antigen recognized by monoclonal 5.1H11; CD56; cell adhesion molecule, neural, 1; MSK 39; MSK39; N-CAM-1; NCAM 1; NCAM; NCAM C; NCAM-1; NCAM1; NCAM1_HUMAN; NCAMC; Neural cell adhesion molecule 1; Neural cell adhesion molecule NCAM; OTTHUMP00000235666
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-6His
Target Protein Sequence	ISVGESKFFLCQVAGDAKDKDISWFSPNGEKLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQKLMFKNAPTPQEFREGEDAVIVCDVVSSLPPTIIWKHKGRDVILKKDVRFIVLSNNYLQIRGIKKTDEGTYRCEGRILARGEINFKDIQVIVNVPPTIQARQNIVNATANLGQSVTLVCDAEGFPEPTMSWTKDGEQIEQEEDDEKYIFSDDSSQLTIKKVDKNDEAEYICIAENKAGEQDATIHLKVFAKPKITYVENQTAMELEEQVTLTCEASGDPIPSITWRTSTRNISSEEKTLDGHMVVRSHARVSSLTLKSIQYTDAGEYICTASNTIGQDSQSMYLEVQYAPKLQGPVAVYTWEGNQVNITCEVFAYPSATISWFRDGQLLPSSNYSNIKIYNTPSASYLEVTPDSENDFGNYNCTAVNRIGQESLEFILVQADTPSSPSIDQVEPYSSTAQVQFDEPEATGGVPILKYKAEWRAVGEEVWHSKWYDAKEASMEGIVTIVGLKPETTYAVRLAALNGKGLGEISAASEFKTQPVQGEPSAPKLEGQMGEDGNSIKVNLIKQDDGGSPIRHYLVRYRALSSEWKPEIRLPSGSDHVMLKSLDWNAEYEVYVVAE
Expression Range	31-677aa
Protein Length	Partial of isform 2
Mol. Weight	75.9 kDa
Research Area	Neuroscience
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	This protein is a cell adhesion molecule involved in neuron-neuron adhesion, neurite fasciculation, outgrowth of neurites, etc.; (Microbial infection) Acts as a receptor for rabies virus.; (Microbial infection) Acts as a receptor for Zika virus.
Subcellular Location	[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Cell membrane; Single-pass type I membrane protein.; [Isoform 3]: Cell membrane; Lipid-anchor, GPI-anchor.; [Isoform 4]: Cell membrane; Lipid-anchor, GPI-anchor.; [Isoform 5]: Secreted.; [Isoform 6]: Secreted.
Database References	HGNC: 7656 OMIM: 116930 KEGG: hsa:4684 STRING: 9606.ENSP00000318472 UniGene: Hs.503878

Gene Functions References

CD56 is a potentially good immunohistochemical marker for differentiating papillary thyroid carcinoma from other benign follicular lesions of the thyroid PMID: 30173227
TROP-2, SLP-2 and CD56 were effective diagnostic markers for PTC, especially when they were combined to use. PMID: 29951933
evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma, using immunohistochemistry PMID: 30188764
Plasma levels of NCAM-1 were found to be lower in coronary artery disease patients compared to controls. PMID: 29506702
CD200(+) and/or CD56(+) positive expression in B-ALL patients at diagnosis is a poor prognostic biomarker. PMID: 29161980
CD56 immunohistochemistry can be useful in differentiating follicular variant papillary thyroid carcinoma from follicular adenoma. PMID: 29799356
NCAM1 protein expression levels were found to be regulated by miRNA-572 in an oligodendroglial cell line. PMID: 28332001
a role for CD56 in developmental synapse structure, natural killer (NK) cell motility and NK cell development. PMID: 27435370
The expression of CD56 was analyzed in 74 samples of primary MM cells collected from patients before they received bortezomib plus dexamethasone therapy. Expression of NCAM was lower among patients who responded poorly. In vitro expression of NCAM induced by transfection of MM cells enhanced their sensitivity to Btz treatment by causing accumulation of polyubiquitinated proteins. PMID: 29738534
Results show that the conjugate selectively depleted the CSC population of the tumors and effectively inhibited tumor growth without causing toxicity. We propose that the NCAM-targeted conjugate could be an effective therapeutic for Wilms tumor. PMID: 28729402
CD200 and/or CD56 positive expression in B-ALL at diagnosis suggest a poor prognosis and may be associated with biological aggressiveness. PMID: 29144828
This study concludes that the cytotoxic action of CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly due to the natural killer cells. PMID: 27136441
NCAM1 was up-regulated in the malignant Middle Cerebral Artery Infarction. PMID: 28828208
This supports the conclusion that a lower proportion of CD56(bright) natural killer regulatory cells results in the high rate of chronic graft-versus-host disease seen in filgrastim-stimulated apheresis peripheral blood. PMID: 28935847
inhibiting NCAM1 would be cardioprotective, counteract the pathological action of TGFbeta1 and reduce heart failure severity. PMID: 28870505
Mutation of a putative MAP kinase (Erk2) consensus site regulates neural cell adhesion molecule (NCAM) endocytosis and NCAM-dependent neurite outgrowth. PMID: 28193531
The combined use of CK19 and CD56 is helpful in discriminating papillary thyroid carcinoma and its variants from other mimicking thyroid lesions. PMID: 28214214
NCAM-expression in adult dilated cardiomyopathy hearts is associated with cardiomyocyte hypertrophy. PMID: 28343767
This study identified NCAM1 gene sets related to self-reported depression scores in healthy participants PMID: 28334615
Basal cell carcinoma (BCC) typically shows patchy CD56 expression and diffuse CK5/6 positivity. These 2 markers can be used to distinguish between BCC and Merkel cell carcinoma in challenging cases. PMID: 28403527
Study represents the first to evaluate the prognostic impact of CD56 expression in a real-life setting and address these findings to a large and heterogeneous subset of AML. PMID: 26914377
T-cell differentiation and CD56+ levels are different in polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. PMID: 29165313
findings that the CD56 and CD117 expression levels are lower in advanced stages than earlier stages and that LDH level and CD117 expression have an inverse relationship in patients with newly diagnosed multiple myeloma (MM) suggest that CD56 and CD117 expressions may be prognostic markers for MM. PMID: 28270374
soluble NCAM might be thought as a specific marker of peripheral nerve demyelination and as a sensitive marker of peripheral nerve injuries PMID: 28336415
Neural cell adhesion molecule (NCAM, CD56) is a transmembrane glycoprotein. PMID: 27528376
Suggest that INSM1 is valuable for identification of the high-grade thoracic neuroendocrine carcinomas that are sometimes negative for synaptophysin, chromogranin, and CD56. PMID: 28719469
CD56(bright) NK IL-7Ralpha expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections PMID: 28400540
These findings provide evidence for newly-discovered roles for PREP in mechanisms regulating cellular plasticity through NCAM and PSA-NCAM. PMID: 27566163
NCAM- and FGF-2-mediated FGFR1 signaling in the tumor microenvironment regulates the survival and migration of esophageal squamous carcinoma cells. PMID: 27317650
Study provides detailed description of the PSA-NCAM distribution throughout the human brain and quantitatively compares control, Alzheimer's and Parkinson's disease. Results demonstrate that PSA-NCAM-mediated structural plasticity may not be limited to neurogenic niches and is conserved in the aged brain, provide evidence that PSA-NCAM is reduced in the entorhinal cortex. PMID: 27282086
The purpose of this study is to reveal whether neural cell adhesion molecule (NCAM) mediates the protective effects of GDNF. PMID: 27003822
Suppressor function of CD56bright NK cells is impaired in multiple sclerosis. PMID: 27157273
data provided molecular details about the interaction between HuPrP and the NCAM fibronectin domain, and revealed a new role of PrP(C) N terminus as a dynamic and functional element responsible for protein-protein interaction. PMID: 27535221
The polybasic region of the polysialyltransferase ST8Sia-IV binds directly to NCAM. PMID: 28233978
analysis of structural and genetic features of the CD56 glycoprotein, and summary of its roles in the normal versus diseased metanephric blastema [review] PMID: 27935326
novel RUNX1 isoforms contribute in controlling CD56 expression in acute myeloid leukemia cells. PMID: 26706848
NCAM1 SNPs were associated with lifetime cannabis use, but the association did not reach genome-wide significance. [Meta-Analysis] PMID: 27023175
analysis of natural killer cell markers in renal transplantation that have roles in acute rejection reveals that CD56 and CD57 are increased in the interstitial compartment in donor-specific antibody (DSA)-negative biopsies from patients with acute antibody-mediated rejection without C4d, and CD16 is increased in the glomerular compartment in DSA-positive biopsies PMID: 26615051
Data show that negative selection for CD133 is required for defining NCAM1(+) nephron stem cells in normal and malignant nephrogenesis. PMID: 27020553
Report increased CD56 expression by immature biliary epithelial cells in biliary atresia. PMID: 26937142
NCAM1 deletion is associated with neuroblastoma and ganglioneuroma. PMID: 26463893
this study shows that CD56 expression defines a poor prognosis subset in the cytogenetically intermediate prognosis pediatric AML. PMID: 26147745
The expression of coding and non-coding genes with SAFB1 cross-link sites was altered by SAFB1 knockdown. The isoform-specific expression of neural cell adhesion molecule (NCAM1) and ASTN2 was influenced by SAFB1. PMID: 26694817
the expression of CD56 in adenomyosis is positively associated with the severity of dysmenorrhea. PMID: 26344352
A FOXP3(+)CD3(+)CD56(+)-expressed T-cell population with immunosuppressive function and reduced patient survival has been identified in cancer tissues of human hepatocellular carcinoma. PMID: 26437631
NK cell maturation to CD56(dim) subset associated with high levels of NCRs overrides the inhibitory effect of NKG2A and recovers impaired NK cell cytolytic potential after allogeneic hematopoietic stem cell transplantation. PMID: 26856773
The neural cell adhesion molecule (NCAM) is a glycoprotein implicated in cell-cell adhesion, neurite outgrowth and synaptic plasticity. PMID: 26460482
L1-CAM and N-CAM: From Adhesion Proteins to Pharmacological Targets PMID: 26478212
CD56 marker is a useful alternative that is comparable to SSTR2A for the diagnosis of phosphaturic mesenchymal tumors. PMID: 26339384
Case Report: chronic lymphocytic leukemia with aberrant CD56 and CD57 expression. PMID: 26013700

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.